The estimated Net Worth of Edgardo Jr Baracchini is at least $320 Thousand dollars as of 9 August 2018. Edgardo Baracchini owns over 50,000 units of INmune Bio stock worth over $80,622 and over the last 11 years Edgardo sold INMB stock worth over $239,528.
Sign up
Edgardo Baracchini INMB stock SEC Form 4 insiders trading
Edgardo has made over 31 trades of the INmune Bio stock since 2015, according to the Form 4 filled with the SEC. Most recently Edgardo exercised 50,000 units of INMB stock worth $552,500 on 9 August 2018.
The largest trade Edgardo's ever made was exercising 50,000 units of INmune Bio stock on 9 August 2018 worth over $552,500. On average, Edgardo trades about 4,945 units every 28 days since 2014. As of 9 August 2018 Edgardo still owns at least 12,941 units of INmune Bio stock.
You can see the complete history of Edgardo Baracchini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Edgardo Baracchini's mailing address?
Edgardo's mailing address filed with the SEC is C/O INMUNE BIO INC,, 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Insiders trading at INmune Bio
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini, and Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
What does INmune Bio do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
What does INmune Bio's logo look like?
Complete history of Edgardo Baracchini stock trades at Xencor Inc and INmune Bio
INmune Bio executives and stock owners
INmune Bio executives and other stock owners filed with the SEC include:
-
Dr. Raymond Joseph Tesi M.D.,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
David J. Moss M.B.A.,
CFO, Treasurer & Sec. -
Dr. Raymond Joseph Tesi,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Christopher J. Barnum,
Director of Neuroscience -
Joshua S. Schoonover Esq.,
Assoc. Gen. Counsel -
Scott Juda,
Director -
Inc Xencor,
-
Timothy J Schroeder,
Director -
Edgardo Jr Baracchini,
Director -
James Kelly Ganjei,
Director -
Linda F Powers,
-
Marcia Allen,
Director -
Raymond Joseph Tesi,
President and CEO -
Mark William Lowdell,
Chief Scientific Officer -
David J Moss,
Chief Financial Officer